Latest filing published 11 Jun 2026 for Corbus Pharmaceuticals Holdings, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Winston Kung, listed as finance chief, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in PMV Pharmaceuticals, Inc., Corbus Pharmaceuticals Holdings, Inc. and Janux Therapeutics, Inc. The record holds 14 filings, for trades running from 3 May 2021 to 10 June 2026.
On the market, this insider has only sold: 1 sale. The totals do not cover 1 filing with an undisclosed amount. Other entries cover 5 share grants and 6 option exercises. In 2026 alone, the filings show no purchases and 1 sale.
The record was last updated on 11 June 2026 with an open-market sale in Corbus Pharmaceuticals Holdings, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations